Sugi Predict

Sugi Predict / Targets / PRKD2

PRKD2

Serine/threonine-protein kinase D2 · Q9BZL6 · PRKD2 on Sugi Atlas →

63,992 patent compounds predicted against PRKD2, 45,084 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL173288 SCHEMBL173288 1.00 5/20
SCHEMBL231766 SCHEMBL231766 0.79 5/20
SCHEMBL128451 SCHEMBL128451 0.49 4/20
SCHEMBL112120 SCHEMBL112120 0.37 4/20
SCHEMBL95142 SCHEMBL95142 1.00 3/20
SCHEMBL124161 SCHEMBL124161 1.00 3/20
Vx-702 Vx-702 (SCHEMBL185712) 1.00 3/20
SCHEMBL226317 SCHEMBL226317 1.00 3/20
Ucn-01 Ucn-01 (SCHEMBL259162) 1.00 3/20
Bi-2536 Bi-2536 (SCHEMBL372489) 1.00 3/20
SCHEMBL376236 SCHEMBL376236 0.88 3/20
SCHEMBL376134 SCHEMBL376134 0.85 3/20
SCHEMBL375839 SCHEMBL375839 0.85 3/20
SCHEMBL375825 SCHEMBL375825 0.83 3/20
SCHEMBL376040 SCHEMBL376040 0.83 3/20
SCHEMBL376263 SCHEMBL376263 0.82 3/20
SCHEMBL376100 SCHEMBL376100 0.81 3/20
SCHEMBL376093 SCHEMBL376093 0.81 3/20
SCHEMBL376152 SCHEMBL376152 0.81 3/20
SCHEMBL94964 SCHEMBL94964 0.79 3/20

Clinical trials — most relevant to PRKD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion PHASE4RECRUITING
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Repurposing Chlorpromazine in the Treatment of Glioblastoma PHASE2UNKNOWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Tabectedin to Treat Children and Adolescents With Cancer PHASE1COMPLETED
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia PHASE1COMPLETED
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD nanNOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKD2 binder may also engage these)

ProteinNameSimilarity
Q5XIS9 — 1.000 Q5XIS9 →
Q8BZ03 — 1.000 Q8BZ03 →
PRKD1 Serine/threonine-protein kinase D1 0.992 landscape →
Q9WTQ1 — 0.989 Q9WTQ1 →
Q62101 — 0.989 Q62101 →
Q8K1Y2 — 0.985 Q8K1Y2 →
PRKD3 Serine/threonine-protein kinase D3 0.977 landscape →
Q8BWW9 — 0.973 Q8BWW9 →
Q9BYZ6 — 0.972 Q9BYZ6 →
Q9HCE6 — 0.971 Q9HCE6 →
A2AWP8 — 0.971 A2AWP8 →
A0A8I5ZNK2 — 0.971 A0A8I5ZNK2 →
F1LTE0 — 0.968 F1LTE0 →
Q6P9R2 — 0.968 Q6P9R2 →
Q9Y2X7 — 0.968 Q9Y2X7 →
Q29RM4 — 0.968 Q29RM4 →
O94844 — 0.968 O94844 →
Q5R5M3 — 0.967 Q5R5M3 →
P43249 — 0.967 P43249 →
O88506 — 0.966 O88506 →
Q2Q1W2 — 0.966 Q2Q1W2 →
Q9Z272 — 0.966 Q9Z272 →
D3ZVM4 — 0.966 D3ZVM4 →
Q9DAK3 — 0.966 Q9DAK3 →
Q99L90 — 0.966 Q99L90 →
Q91V93 — 0.965 Q91V93 →
Q863I2 — 0.965 Q863I2 →
Q9R1D7 — 0.965 Q9R1D7 →
PKN1 Serine/threonine-protein kinase N1 0.965 landscape →
PKN2 Serine/threonine-protein kinase N2 0.965 landscape →